Methods and compositions for treating cancer

JP2024164147AInactive Publication Date: 2024-11-26JANSSEN ONCOLOGY INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024140948
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2006-08-25
Filing Date
2024-08-22
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Benefits of technology

【0008】 (発明の要旨) 本明細書中で説明するのは、酢酸アビラテロン(すなわち、3β-アセトキシ-17-(3-ピリ ジル)アンドロスタ-5,16-ジエン)などの治療上有効な量の17α-ヒドロキシラーゼ/C17,20 -リアーゼ阻害薬を、患者、例えば、それを必要とする患者に、限定はされないが抗癌薬 又はステロイドを含む治療上有効な量の少なくとも1種の追加の治療薬と組み合わせて投 与する、癌の治療方法である。このような方法は、また、現在癌治療を受けている個体を 含む不応性癌を有する個体に対する効果的な治療を提供する。したがって、いくつかの実 施態様において、該方法は、患者の不応性癌を治療することを対象とし、治療上有効な量 の17α-ヒドロキシラーゼ/C17,20-リアーゼ阻害薬を、現在抗癌薬を服用している患者に 投与する。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024164147000001
    Figure 2024164147000001
  • Figure 2024164147000002
    Figure 2024164147000002
  • Figure 2024164147000003
    Figure 2024164147000003
Patent Text Reader

Abstract

To provide pharmaceutical compositions for treating cancer such as prostate cancer.SOLUTION: The present invention provides a pharmaceutical composition for treating prostate cancer comprising abiraterone acetate or a pharmaceutically acceptable salt thereof, and prednisolone, wherein, the abiraterone acetate or the pharmaceutically acceptable salt thereof and the prednisolone are administered in therapeutically effective doses, either in combination or separately.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION Described herein are methods and compositions for treating cancer. More particularly, The method for treating cancer includes administering abiraterone acetate (i.e., 3β-acetoxy-17-(3-pyridyl) 17α-hydroxylase / C such as androsta-5,16-diene) 17,20 -Lyase Inhibition The drug is administered in combination with at least one additional therapeutic agent, such as an anticancer drug or a steroid. In addition, 17α-hydroxylase / C 17,20 -lyase, and anticancer drugs or steroids a few steroids, such as corticosteroids, or more specifically glucocorticoids; Disclosed are compositions that include at least one additional therapeutic agent. [Background technology]

[0002] (background) The number of people being diagnosed with cancer has increased significantly. and individuals diagnosed with an estrogen-dependent disorder, such as breast cancer. Because the number of such diagnoses is increasing at an alarming rate.

[0003] Prostate cancer is currently the most common non-skin cancer and the leading cause of cancer-related deaths in men. It is the second leading cause of cancer after lung cancer among men with organ-confined prostate cancer. The most common treatments are prostatectomy or radiation therapy. These treatments are highly invasive and Not only is this treatment costly, it also has undesirable side effects and such localized treatments are difficult to treat. Furthermore, a large percentage of individuals who receive localized treatment develop recurrent cancer. Suffers from.

[0004] Furthermore, the incidence of breast cancer in women has increased from 1 in every 20 women in 1960 to 8 in every 20 women in 2005. In addition, breast cancer is most prevalent among white and African-American women. It is a common cancer. Like treating prostate cancer, most treatments for women diagnosed with breast cancer are All options are highly invasive and have significant side effects. , surgery, radiation and chemotherapy.

[0005] Hormonal therapy is another treatment option for individuals diagnosed with prostate or breast cancer. Hormone therapy is a form of systemic treatment for prostate or breast cancer that uses hormones. Using drugs to remove estrogen and progesterone from the body, which are thought to promote the growth of breast cancer and testosterone and dihydrotestosterone, which are thought to promote the growth of prostate cancer. It suppresses the production of hormones such as testosterone or blocks the effects of hormones. Additionally, hormone therapy is less invasive than surgery and avoids the side effects associated with chemotherapy or radiation. Hormonal therapy may also be used alone or in addition to topical therapy. and has been shown to be effective in individuals whose cancer is metastatic.

[0006] Hormonal therapy can be used for less aggressive and more advanced stages of cancer, but However, some individuals currently treated with hormone therapy do not respond significantly to such treatment. may not show any response or may not show any response at all. Additionally, some patients treated with current hormone therapy treatments may develop recurrent or recurrent cancer. Currently, patients with such refractory cancers have very few treatment options left. Summary of the Invention [Problem to be solved by the invention]

[0007] Despite the advances made in cancer treatment, cancers such as, but not limited to, prostate and breast cancer remain a major concern. There remains a need for more effective strategies to treat cancer. There is a need for effective anti-cancer treatment options for patients who do not respond to current chemotherapy. There is a need for effective anti-cancer treatment options for patients with recurrent cancer. [Means for solving the problem]

[0008] Summary of the Invention Described herein is abiraterone acetate (i.e., 3β-acetoxy-17-(3-pyridyl) A therapeutically effective amount of 17α-hydroxylase / C, such as androsta-5,16-diene. 17,20 -lyase inhibitors to a patient, such as, but not limited to, an anticancer drug or in combination with a therapeutically effective amount of at least one additional therapeutic agent, including a steroid. Such methods also include treating individuals currently undergoing cancer treatment with Thus, some studies have demonstrated that the use of cyclosporine in patients with refractory cancers, including bronchial asthma, may be effective in treating these cancers. In an embodiment, the method is directed to treating a refractory cancer in a patient, comprising administering a therapeutically effective amount of 17α-hydroxylase / C 17,20 -Lyase inhibitors in patients currently taking anticancer drugs Administer.

[0009] For example, in some embodiments, the method for treating cancer in a mammal comprises administering to the mammal a dose of about 0.01 Abiraterone acetate in amounts of about 0.1 mg / m2 ~about 20mg / m 2 The amount of Administering toxantrone.

[0010] In another embodiment, the method for treating cancer in a mammal comprises administering from about 0.01 mg / kg / day to about 10 Abiraterone acetate at a dose of about 1 mg / m 2 ~about 175mg / m 2 A dose of paclitaxel This includes administering.

[0011] In yet another embodiment, the method for treating cancer in a mammal comprises administering about 0.01 mg / kg / day Abiraterone acetate in an amount of about 100 mg / kg / day, and about 1 mg / m 2 ~about 100mg / m 2 Doses of docetaxel The method includes administering

[0012] Further described herein is a combination of abiacetamin in an amount of about 0.01 mg / kg / day to about 100 mg / kg / day. and administering leuprolide in an amount of about 0.01 mg to about 200 mg. A method for treating cancer in a subject, wherein leuprolide is administered for about 3 days to about 12 months. It is administered over a period of time.

[0013] In another embodiment, the method for treating cancer in a mammal comprises administering from about 0.01 mg / kg / day to about 10 0 mg / kg / day of abiraterone acetate and about 0.01 mg to about 20 mg of goserelin. wherein the goserelin is administered for about 28 days to about 3 months.

[0014] In yet another embodiment, the method for treating cancer in a mammal comprises administering about 0.01 mg / kg / abiraterone acetate in an amount of about 0.01 mg to about 20 mg / kg / day; and triptorelli in an amount of about 0.01 mg to about 20 mg / kg / day. wherein the triptorelin is administered for about one month. .

[0015] The method of treating cancer in a mammal also includes administering acetaminophen in an amount of about 0.01 mg / kg / day to about 100 mg / kg / day. Biraterone, and seocalcitol in an amount of about 0.1 μg / day to about 500 μg / day, e.g., about 100 μg The method may include administering seocalcitol per day.

[0016] Also, the method for treating cancer in a mammal includes administering an amount of from about 0.01 mg / kg / day to about 100 mg / kg / day of abiraterone acetate and bicalutamide in an amount of about 1 mg / day to about 300 mg / day. It is possible.

[0017] In yet another embodiment, the method for treating cancer in a mammal comprises administering about 0.01 mg / kg / day Abiraterone acetate in an amount of about 100 mg / kg / day, and flutamide in an amount of about 1 mg / day to about 2000 mg / day. The method can include administering

[0018] Additionally, the method for treating cancer in a mammal includes administering acetone in an amount of about 50 mg / day to about 2000 mg / day. Biraterone, and including but not limited to hydrocortisone, prednisone or dexamethasone The method may include administering a glucocorticoid in an amount of about 0.01 mg / day to about 500 mg / day. can.

[0019] Also described herein is a therapeutically effective amount of at least one 17α-hydroxylase. Rase / C 17,20-Lyase inhibitors, including but not limited to mitoxantrone, paclitaxel le, docetaxel, leuprolide, goserelin, triptorelin, seocalcitol, bicalutamide, flutamide, or steroids (including but not limited to hydrocortisone, prednisolone, and administering to the subject a therapeutically effective amount of at least one additional anti-inflammatory drug, such as a steroid, such as doxorubicin, thiazolinone, or dexamethasone. A composition for treating cancer comprising a combination with a cancer drug.

[0020] Finally, the abiraterone acetate and the glucocorticoid are optionally combined with a carrier, diluent or excipient. A single unit dosage form containing at least one 17α-hydroxylase with an excipient is contemplated. Z / C 17,20 -lyase inhibitor and an additional anti-cancer drug or steroid are envisaged. For example, the kit may include a vial containing abiraterone acetate and a glucocorticoid. The container may include another vial containing

[0021] (definition) As used herein, and unless otherwise defined, the word "cancer" refers to a cancer that is caused by a This refers to abnormal cell growth, division or proliferation in the body. Cancers that can be treated with this method include, but are not limited to, prostate cancer, breast cancer, adrenal cancer, leukemia, and lymphoma. , myeloma, Waldenström's macroglobulinemia, monoclonal gammopathy , benign monoclonal gammopathy, heavy chain disease, sarcoma of bone and connective tissue, brain tumor, thyroid Adenocarcinoma, pancreatic cancer, pituitary cancer, eye cancer, vaginal cancer, vulvar cancer, cervical cancer, uterine cancer, ovarian cancer, esophageal cancer, stomach Cancer, colon cancer, rectal cancer, liver cancer, gallbladder cancer, bile duct carcinoma, lung cancer, testicular cancer, penile cancer, oral cancer, skin Cancer, kidney cancer, Wilms' tumor, and bladder cancer.

[0022] As used herein, and unless otherwise defined, the terms "treat" and "treat" refer to and "treatment" includes the curing of tumors, or primary, localized, or metastatic cancer cells or tissues. , elimination, mitigation, management or control, and minimizing or slowing the spread of cancer.

[0023] As used herein, and unless otherwise defined, the term "patient" refers to an animal. This refers to animals, including but not limited to humans, monkeys, cows, horses, sheep, pigs, chickens, rats, etc. Animals such as turkeys, quails, cats, dogs, mice, rats, rabbits, or guinea pigs In one embodiment, the patient is a mammal, and in another embodiment, the patient is In some embodiments, the patient may be an adult male or female. In one embodiment, the patient is a male, between about 30 and about 85 years of age. In certain embodiments, the patient is a woman between about 30 and about 85 years of age. In a further embodiment, the patient is predisposed to the tumor (e.g., due to genetic or environmental factors). In another embodiment, the patient has or is predisposed to a tumor (e.g., due to genetic or environmental factors). The patient may be castrated or non-castrated.

[0024] The term "17α-hydroxylase / C 17,20 As used herein, "-lyase inhibitor" refers to If, 17α-hydroxylase / C 17,20 -lyase (an enzyme involved in testosterone synthesis) inhibition refers to a drug, its analogues, its derivatives, its metabolites, or its pharma- ceutical acceptable salts. In addition, unless otherwise stated, the specific 17α-hydroxylase / C 17,20 -Lyase inhibitors and the specific 17α-hydroxylase / C 17,20 -Lyase inhibitor analogues, derivatives The compound may include the compound itself, a metabolite, or a pharma- ceutical acceptable salt.

[0025] The term "anticancer drug" as used herein refers to a drug that directly or indirectly kills cancer cells. any treatment that directly or indirectly prevents, stops or reduces the proliferation of cancer cells Throughout this specification and in the claims, the phrase "anticancer drug" refers to a singular noun, e.g. For example, the term "anticancer drug" or "the anticancer drug" is used, but the phrase "anticancer drug" refers to only one anticancer drug. Note that this should not be construed as being limited to the incorporation of cancer drugs.

[0026] As used herein, and unless otherwise defined, the phrase "therapeutically effective amount" refers to a " is 17α-hydroxylase / C 17,20 -When used in relation to lyase inhibitors or therapeutic agents In this case, the 17α-hydroxylase is effective for treating a disease or disorder disclosed herein, such as cancer. Silase / C 17,20 - the amount of lyase inhibitor or therapeutic agent.

[0027] As used herein, and unless otherwise defined, the phrase "refractory cancer" means: It means a cancer that has not responded to anti-cancer treatment or that has responded poorly to anti-cancer treatment. Refractory cancers can also include recurrent or recurrent cancers.

[0028] As used herein, and unless otherwise defined, the phrase "refractory patient" means , refers to patients with refractory cancer.

[0029] As used herein, and unless otherwise defined, the phrase "recurrent cancer" means A cancer that has been responsive to anticancer treatment for some time but is no longer responsive to such treatment or is no longer By "progressing," we mean a cancer that no longer responds adequately to conventional treatment.

[0030] As used herein, and unless otherwise defined, the phrase "recurrent cancer" means any of the following: Patients may have been diagnosed with cancer at an earlier stage, been treated for cancer, or may have had a previous non-cancerous diagnosis. This means the cancer has returned to normal.

[0031] As used herein, and unless otherwise defined, the term "derivative" means A chemically modified compound, the chemical modification being carried out at one or more functional groups of the compound. Derivatives may retain or improve the pharmacological activity of the compound from which they are derived. There is.

[0032] As used herein, and unless otherwise defined, the term "analog" means Structurally similar to another, but with a slightly different composition (one atom replaced by a different element) The term refers to compounds in which certain atoms are replaced with other atoms, or certain functional groups are present.

[0033] As used herein, and unless otherwise defined, the phrase "pharmaceutical acceptable The salts that can be used to treat 17α-hydroxylase / C 17,20 -Maintains biological availability of lyase inhibitors 17α-hydroxylase / C 17,20 - Refers to any salt of a lyase inhibitor. Acceptable salts include, but are not limited to, acetate, sulfate, pyrosulfate, bisulfate, sulfite, etc. Salt, bisulfite, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrrophosphate Acid salts, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates , acrylate, formate, isobutyrate, caproate, heptanoate, propiolate , oxalate, malonate, succinate, suberate, sebacate, fumarate, malate Leyne salt, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate , methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate , phthalates, sulfonates, xylene sulfonates, phylacetate , phenylpropionate, phenylbutyrate, citrate, lactate, gamma-hydroxybutyrate salts, glycolates, tartrates, alkanesulfonates (e.g., methanesulfonates or mesylate), propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate Some officially recognized salts include the sulfonate and mandelate salts. The Science and Practice of Pharmacy (Mack Publ. Co., Easton). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0034] Detailed Description of the Invention The methods described herein for treating cancer include administering to a mammal, preferably a human, an anti-cancer drug or In addition to at least one therapeutic agent such as a steroid, particularly a glucocorticoid, 17α- Hydroxylase / C 17,20 - administering a lyase inhibitor. The substance is 17α-hydroxylase / C 17,20 -Lyase inhibitors, and anticancer drugs or steroids, especially and at least one additional therapeutic agent, such as a corticosteroid or glucocorticoid. This may include administration of additional anti-cancer drugs, radiation therapy, chemotherapy, photodynamic therapy, surgery, or other Other anti-cancer treatments, such as immunotherapy, can be used in conjunction with the methods and compositions.

[0035] (17α-hydroxylase / C 17,20 -Lyase inhibitors) US Pat. No. 5,604,213 to Barrie et al., which is incorporated herein by reference in its entirety. As described in No. 17,20 -Lyase inhibitors are used in the treatment of cancer, especially androgen-dependent and estrogen-dependent disorders such as prostate cancer and breast cancer, respectively. It has been shown to be useful in the treatment of hormone-dependent disorders.

[0036] In some embodiments, 17α-hydroxylase / C 17,20 -lyase inhibitors are 17- (3-pyridyl)androsta-5,16-dien-3β-ol; 17-(3-pyridyl)androsta-3,5, 16-Triene;17-(3-pyridyl)androsta-4,16-dien-3-one;17-(3-pyridyl)est 17-(3-pyridyl)-5α-androst-16-ene-3α -ol;17-(3-pyridyl)-5α-androst-16-en-3-one;17-(3-pyridyl) -Androsta-4,16-diene-3,11-dione; 17-(3-pyridyl)-androsta-3,5,16-triene 6α- and 6β-fluoro-17-(3-pyridyl)androsta-4,16-dien-3-one; 17-(3-pyridyl)androst-4,16-diene-3,6-dione; 3α-trifluoromethyl-17-(3- pyridyl)androst-16-en-3β-ol; or their acid addition salts and 3-esters, and metabolites, analogs, derivatives, or pharma- ceutically acceptable salts thereof.

[0037] In some embodiments, 17α-hydroxylase / C 17,20 -lyase inhibitors are represented by the formula ( I) may have the structure: [ka] During the ceremony, X is, but is not limited to, androstane-3α- or 3β-ol; androst-5-ene-3 α- or 3β-ol;Androst-4-en-3-one;Androst-2-ene;Androst-4- Androsta-5,7-dien-3α or 3β-ol; Androsta- 1,4-dien-3-one;Androsta-3,5-diene;Androsta-3,5-dien-3-ol;Es 1,3,5

[10] -Tra-1,3,5

[10] -triene; 1,3,5

[10] -estra-trien-3-ol; 5α-androstan- 3-one;Androst-4-ene-3,11-dione;6-Fluoroandrost-4-en-3-one;or androstane-4-ene-3,6-dione, which may be a steroid residue, A, B and C rings; Each may be further derivatized, if structurally permitted, in one or more of the following ways: The manner in which the ester is formed includes, but is not limited to, 3-ester formation; 5,6-, 6,7-, 7,8-, 9,1 Having one or more carbon or carbocyclic double bonds in either the 1- or 11- or 12-position; 3-oxime as;3-methylene as;3-carboxylate as;3-nitrile as;3-nitro as 3-Deoxy derivatives; A, B or C rings may contain one or more hydroxy, halo, 1~4 -alkyl, Trifluoromethyl, C 1~4 -Alkoxy, C 1~4 -Alkanoyloxy, benzoyloxy , oxo, methylene or alkenyl substituents; or 19-nor; Re; R represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; R 14 represents a hydrogen atom, a halogen atom, or an alkyl group having 1 to 4 carbon atoms; R 15 Each of the substituents is independently a hydrogen atom, or an alkyl or represents an alkoxy group, a hydroxy group, or an alkylcarbonyloxy group having 2 to 5 carbon atoms. or together represent an oxo or methylene group, or R 14 and one R 15 The base is the same represents a double bond, and the remaining R 15 The group is a hydrogen atom or a group having 1 to 4 carbon atoms. represents an alkyl group; and R 16 represents a hydrogen atom, a halogen atom, or an alkyl group having 1 to 4 carbon atoms, In the form of a free base or a pharma- ceutically acceptable acid addition salt, 3β-acetoxy-17-(3- Lysyl)androsta-5,14,16-triene, 3β,15α- and 3β,15β-diacetoxy-17-(3- pyridyl)androsta-5,16-diene and 3β-methoxy-17-(3-pyridyl-5α-andros Excluding To-16-En. Suitable inhibitors also include metabolites, derivatives, analogs, or pharma- ceutically acceptable salts of formula (I). Included.

[0038] In another embodiment, 17α-hydroxylase / C 17,20 The lyase inhibitor has the structure of formula (I) Construction [ka] wherein R represents hydrogen or a lower acyl group having 1 to 4 carbon atoms. Suitable inhibitors also include derivatives, analogues, or pharma- ceutically acceptable salts of formula (I). can be.

[0039] In yet another embodiment, 17α-hydroxylase / C 17,20 -lyase inhibitors are The alkanoyloxy group has 2 to 4 carbon atoms, lysyl)androsta-5,16-diene.

[0040] In a preferred embodiment, 17α-hydroxylase / C 17,20 -Lyase inhibitors are Abiraterone acetate or 3β-acetoxy-17-(3-pyridyl)androsta-5,1 6-dienes, and pharma- ceutically acceptable salts thereof. [ka]

[0041] Preferred salts of abiraterone acetate, and methods for making such salts, are also incorporated herein by reference in their entirety. No. 60 / 603,559 to Hunt, which is incorporated herein by reference. Preferred salts include, but are not limited to, acetates, citrates, lactates, alkanesulfones, etc. These include salts of acetic acid, such as salts of acetic acid, acid salts (e.g., methanesulfonates or mesylates), and salts of tartrates. The mesylate of abiraterone acetate (i.e., 3β-acetoxy) has the following structural formula: androsta-5,16-diene mesylate). [ka]

[0042] 17α-hydroxylase / C 17,20 The -lyase inhibitor can be administered according to any method known to those skilled in the art. For example, such inhibitors can be prepared by the methods described in the literature, which are incorporated herein by reference. According to the methods disclosed in U.S. Pat. No. 5,604,213 and U.S. Pat. No. 5,618,807 to Barrie et al. Can be synthesized. 17α-hydroxylase / C 17,20 -See also other methods of producing lyase inhibitors. No. 60 / 603,558 to Bury, which is incorporated herein by reference. .

[0043] 17α-hydroxylase / C administered to a mammal having cancer 17,20 -Lyase inhibitor dosage 17α-hydroxylase / C 17,20 Lyase inhibitors, either alone or as an additional anticancer Whether administered in combination with additional anti-cancer treatments such as drugs, It is an amount in minutes.

[0044] (Additional Therapeutic Drugs) 17α-hydroxylase / C 17,20 -Use as an anticancer drug in addition to lyase inhibitors Suitable compounds that can be used include, but are not limited to, hormone ablation agents, antiandrogens, differentiation agents, and the like. Stimulators, antitumor agents, kinase inhibitors, antimetabolites, alkylating agents, antibiotics, immunological agents agents, interferon-type agents, intercalation agents, growth factor inhibitors, cell cycle inhibitors Drugs, enzymes, topoisomerase inhibitors, biological response modifiers, mitotic inhibitors, matrix These include anti-androgen drugs, gene therapy drugs, and anti-cancer drugs. The amount of additional anticancer drug administered to a mammal, whether administered alone or in combination with a 17α-hydroxy Rase / C 17,20 -To treat cancer, either in combination with a lyase inhibitor Below are listed some examples of anticancer drugs in the above categories. The following examples are intended to be illustrative and not limiting. Many may be listed in multiple classes of anticancer drugs and are not in any way classified as such. It is not limited to the categories listed.

[0045] Suitable hormone ablation agents include, but are not limited to, androgen ablation agents and estrogen In a preferred embodiment, the 17α-hydroxylase / C 17,20 -Rear The hormonal inhibitors include deslorelin, leuprolide, goserelin, or triptorelin. Throughout this specification and in the claims, the phrase "hormones" is used in combination with a hormone-removing drug. "Hormone ablation drug" is used as a singular noun, e.g., "the hormone ablation drug" or "the hormone ablation drug." Although stated, the phrase "hormone ablative" is not limited to the inclusion of only one hormone ablative. The amount of hormone ablation drug administered to a mammal with cancer should not be construed as being solely Administered alone or with 17α-hydroxylase / C 17,20 - Administered in combination with lyase inhibitors Either way, it is an amount that is sufficient to treat the cancer.

[0046] Suitable antiandrogens include, but are not limited to, bicalutamide, flutamide and nil. The amount of antiandrogen administered to a mammal with cancer is or 17α-hydroxylase / C 17,20 -Whether to administer in combination with lyase inhibitors In any case, the amount is sufficient to treat the cancer.

[0047] In another embodiment, 17α-hydroxylase / C 17,20 -Lyase inhibitors promote differentiation Suitable differentiation-inducing agents include, but are not limited to, polyamine inhibitors; Vitamin D and its analogues (calcitriol, doxorcalciferol and seocalciferol) tol, etc.); vitamin A metabolites (ATRA, retinoic acid, retinoids, etc.); short-chain fatty acids; phenyl butyrate; and nonsteroidal anti-inflammatory drugs. The amount of differentiation agent administered alone or in combination with 17α-hydroxylase / C 17,20 -Lyase Inhibition Regardless of whether it is administered in combination with a drug, it is in an amount that is sufficient to treat the cancer.

[0048] In another preferred embodiment, 17α-hydroxylase / C 17,20 -Lyase inhibitors are It may be administered in combination with an anti-tumor drug, including but not limited to, tubulin. Drugs that interact with nicotinamide, topoisomerase inhibitors, and drugs such as acitretin, alstonine, and alstonine. Monafide, amphetinile, amsacrine, anquinomycin, anti Neoplaston, aphidicolin glycinate, asparaginase, baccarin, batracy Phosphorus, Benfluron, Benzotript, Bromophosphamide, Caracemide, Carmethine Hydrochloride Zoll, chlorsulfaquinoxalone, clanfenur fenur), claviridinone, crisnatol, curaderm, cytarabine, cytosine tin, dacarbazine, datertinium, dihematoporphyrin ether, dihydrolene Peron, dinaline, distamycin, docetaxel, elipravine, elliptinium acetate , epothilone, ergotamine, etoposide, etretinate, fenretinide, gallium nitrate Um, genkwadaphnin, hexadecylphosphocholine, homoharringtonine homoharringtonine, hydroxyurea, irmophosine, isoglutamine, isotrexate Tinoin, leukoregulin, lonidamine, merbarone, merocyanine derivatives Body, methylanilinacridine, minactivin, mitonafide, mitoxin, mitoxan Thoron, mopidamol, motretinide, N-(retinoyl)amino acids, N-acylated dehydro Alanine, nafazatrom, nocodazole derivatives, octreotide, oxanocin, paclitaxel Taxel, pancratistatin, pazelliptin, piroxantrone, polyhematoporphyrin Phosphorus, polybutene, probimane, procarbazine, proglumide, razoxane, leteri Putin, Spatol, Spirocyclopropane derivatives, Spirogermanium, Stripolgi Non, Superoxide Dismutase, Teniposide, Salivlastin, Tocotrienol , Topotecan, Ukrain, Vinblastine sulfate, Vincristine, Vindesine, Vines These include thoramide, vinorelbine, vintriptol, vinzolidine, and withanolides. The amount of antineoplastic agent administered to a mammal having cancer may be determined by the amount of the agent administered alone or in combination with a 17α-hydrogenase. Xylase / C 17,20 -Treat cancer, whether administered in combination with a lyase inhibitor is an amount sufficient to

[0049] 17α-hydroxylase / C 17,20 -Lyase inhibitors include p38 inhibitors and CDK inhibitors. Enzyme inhibitors, TNF inhibitors, metal matrix protease inhibitors (MMPs), COX-2 inhibitors (Ce Includes recoxib, rofecoxib, parecoxib, valdecoxib and etoricoxib. ), SOD mimic, or α v It can also be used in combination with a β3 blocker. The amount of kinase inhibitor administered may vary depending on whether it is administered alone or in combination with 17α-hydroxylase / C 17,20 - Either combination with a lyase inhibitor is sufficient to treat cancer. The quantity.

[0050] In another embodiment, 17α-hydroxylase / C 17,20 -Lyase inhibitors are metabolic antagonists Suitable antimetabolites include, but are not limited to, 5-FU-fibrinogen. folic acid, aminothiadiazole, brequinar sodium um, carmofur, cyclopentylcytosine, cytarabine stearate phosphate, cytarabin Bin complex, desaguanine, dideoxycytidine, dideoxyguanosine, didox, Doxifluridine, Fazarabine, Floxuridine, Fludarabine phosphate, 5-fluoro Uracil, N-(2'-furanidyl)-5-fluorouracil, isopropylpyrrolidine, methophen Zaprim, methotrexate, norspermidine, pentostatin, piritrexim, Ricamycin, thioguanine, tiazofurin, trimetrexate, tyrosine kinase inhibitors The amount of antimetabolite administered to a mammal having cancer can be selected from the group consisting of anticancer drugs, anticancer drugs, and urishitin. is administered alone or in combination with 17α-hydroxylase / C 17,20 -In combination with lyase inhibitors Whatever amount is administered will be in an amount sufficient to treat the cancer.

[0051] In another embodiment, 17α-hydroxylase / C 17,20 -lyase inhibitors are Suitable alkylating agents include, but are not limited to, aldo-phosphatase inhibitors. Mido analogues, altretamine, anaxylon, bestravsil, budotitan, carbopra cisplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, ciplatin cyplatate, diphenylspiromustine, diplatinum cytostatics, ermustine, Elamustine sodium phosphate, fotemustine, hepsul-fam, ifo Sulfamide, iproplatin, lomustine, mafosfamide, mitolactol, oxalate Riplatin, Prednimustine, Ranimustine, Semustine, Spiromustine, Tauromucin Select from tetracycline, temozolomide, teroxylon, tetraplatin, and trimelamol. The amount of alkylating agent administered to a mammal having cancer may be determined by the amount of the alkylating agent administered alone or in combination with 17α- Hydroxylase / C 17,20 -Cancer, whether administered in combination with a lyase inhibitor is an amount that is sufficient to treat

[0052] In another preferred embodiment, 17α-hydroxylase / C 17,20 -Lyase inhibitors are It may be administered with an antibiotic. Suitable antibiotics include, but are not limited to, aclarubicin, Actinomycin D, Actinoplanon, Adriamycin, Aeroprisinin (aeroplys inin derivatives, amrubicin, anthracycline, azinomycin A, viscaverin, sulfur Bleomycin acid, bryostatin-1, calicheamicin, chromoximycin, dactinoside mycin, daunorubicin, dimethicillin B, dexamethasone, doxorubicin, doxorubicin Xorubicin-fibrinogen, Elsamicin-A, Epirubicin, Erbstatin, E Sorubicin, esperamicin-A1, esperamicin-A1b, fostriecin, glidbak glycine, gregatin-A, glinkamycin, herbimycin, corticosteriocin Idols (hydrocortisone, etc.), idarubicin, iludin, kazusamycin, kesarilodin (kesarirhodin), menogaril, mitomycin, neoenactin, oxalicin, oxalicin Unomycin, peplomycin, pyratin, pirarubicin, polusramycin, prednisolone zolone, prednisolone, pyrindanicin A, rapamycin, rhizoxin, rodorubicin, Sibanomicin, siwenmycin, sorangicin-A, spar Somycin, Tallysomycin, Terpentesin, Sulazin, Triclozaline A, and Sol The amount of antibiotic administered to a mammal having cancer can be selected from or 17α-hydroxylase / C 17,20 -Whether to administer in combination with a lyase inhibitor Either way, the amount is sufficient to treat the cancer.

[0053] Alternatively, 17α-hydroxylase / C 17,20-Lyase inhibitors are also used in other anticancer The anticancer drugs may be used in combination with drugs, including but not limited to acemannan, acetophenone, Larvicin, aldesleukin, alemtuzumab, alitretinoin, altretamine, Amifostine, amsacrine, anagrelide, anastrozole, ancestim, beki Sarotin, Broxuridine, Capecitabine, Celmoleukin, Cetrorelix, Clariax Doribine, clotrimazole, daclizumab, dexrazoxane, dilazep, docosanol bromocriptine, carmustine, cytarabine, diclofenac , edelfosine, edrecolomab, eflornithine, emitefur, exemestane , exisulind, fadrozole, filgrastim, finasteride, Fludarabine phosphate, formestane, fotemustine, gallium nitrate, gemcitabine, Glycopin, heptaplatin, ibandronic acid, imiquimod, iobenguane, irinotecan Can, irsogladine, lanreotide, leflunomide, lenograstim, lentinan sulfate , letrozole, liarozole, lobaplatin, lonidamine, masoprocol, melarso Prole, metoclopramide, mifepristone, miltefosine, millimostim, mito Guazon, Mitolactol, Molgramostin, Nafarelin, Nartograstin, Neda Platinum, nilutamide, noscapine, oprelvekin, osaterone, oxaliplatin, Pamidronate, pegaspargase, sodium pentosan polysulfate, pentostatin, Sibanil, pirarubicin, porfimer sodium, raloxifene, raltitrexate , rasbricase, rituximab, romurtide, sargramostin, sizofiran, so Buzoxane, Sonermin, Suramin, Tasonermin, Tazarotene, Tegafur, Temopol Fin, temozolomide, teniposide, tetrachlorodecaoxide, thalidomide, thymal Fascin, thyrotropin alpha, topotecan, toremifene, trastuzumab, treosulf Fan, tretinoin, trilostane, trimetrexate, ubenimex, valrubicin Anticancer agents administered to mammals with cancer include vinorelbine, verteporfin, and vinorelbine. The dose of the drug is determined by whether it is administered alone or by increasing the 17α-hydroxylase / C 17,20 -In combination with lyase inhibitors Either combination of the two is sufficient to treat the cancer.

[0054] 17α-hydroxylase / C 17,20 -lyase inhibitors are also used in combination with corticosteroids or glucocorticoids. It may be administered or combined with steroids such as glucocorticoids. Hydroxylase / C 17,20 - The lyase inhibitor and the steroid may be in the same or different compositions. Non-limiting examples of suitable steroids include hydrocortisone, prednisone, or dexamethasone. The amount of steroid administered to a mammal with cancer may vary from single Administered alone or with 17α-hydroxylase / C 17,20 - Administered in combination with lyase inhibitors Either way, it is an amount that is sufficient to treat the cancer.

[0055] In one embodiment, provided herein is a method for the treatment of abiraterone acetate and a steroid (e.g., In particular, corticosteroids, more particularly glucocorticoids, are also included in the methods and compositions. Steroids encompassed within the scope of the present disclosure include, but are not limited to, (1) hydrochloride, Cortisone (CORTISOL; CYPRIONATE (eg, CORTEF) oral; sodium phosphate salt Injection (HYDROCORTONE PHOSPHATE); Sodium succinate (e.g., A-HYDROCORT, Solu-CO RTEF); cortisone acetate, oral or injectable form, etc.); (2) dexamethasone (e.g., deca (3) Prednisolone (e.g., Delta-CORTEF, Prednisolone acetate (ECONOPRED), prednisolone sodium phosphate (HYDELTRASOL), donisolone tebutate (e.g., HYDELTRA-TBA), or (4) prednisone (e.g., DELTASONE, ), and combinations thereof (e.g., Goodman and Gilman's Goodman & Gilman's The Pharmacological Basis of Therapeutics (10th ed., 2 001)).

[0056] In certain embodiments, abiraterone acetate in an amount of about 50 mg to about 300 mg, and about 0.5 mg to about A single composition containing steroids in an amount of 3.0 mg, optionally including excipients, carriers, diluents, etc. Single unit solid oral dosage forms are envisaged that include a glucocorticoid at 200 mg / kg or more per dose. The dosage form contains about 250 mg of abiraterone acetate and about 1.0 mg, 1.25 mg, 1.5 mg, or 2.0 mg of steroids. steroids (such as, but not limited to, corticosteroids or glucocorticoids) can be done.

[0057] (17α-hydroxylase / C 17,20 - Administration of lyase inhibitors and additional therapeutic agents) 17α-hydroxylase / C 17,20-Lyase inhibitors, and additional drugs such as anticancer drugs or steroids The additional therapeutic agent can be administered by any method known to one of skill in the art. In some embodiments, 17α-hydroxylase / C 17,20 -Lyase inhibitors and additional therapeutic agents should be administered separately prior to administration. Alternatively, the composition may be 17α-hydroxylase / C 17,20 -Lyase inhibitors and add-ons The therapeutic agents may be combined into a single composition for administration.

[0058] 17α-hydroxylase / C 17,20 - The lyase inhibitor and additional therapeutic agent may be administered sequentially or simultaneously. When administered sequentially, the order of administration is flexible, e.g., 17α- Hydroxylase / C 17,20 -Lyase inhibitor acetate should be administered prior to administration of additional therapeutic agents. Alternatively, administration of an additional therapeutic agent can be 17,20 -Lyase This may precede administration of the inhibitor.

[0059] Whether the agents are administered as separate compositions or in a single composition In any event, each composition is preferably pharma- ceutical suitable for administration. , 17α-hydroxylase / C 17,20 -Lyase inhibitors and therapeutic agents, if administered separately, The administration routes can be the same or different. Examples of administration routes include parenteral (e.g., subcutaneous, intramuscular) Intraorbital, intracapsular, intrathecal, intrasternal, intravenous, intradermal, intraperitoneal, intraanal, intraarterial, intrathecal, transvenous mucosal, intra-articular, and intrapleural; percutaneous (e.g., topical), epidural, and mucosal (e.g., intranasal) injections injection or infusion; as well as oral, inhalation, pulmonary, and rectal administration. Both are administered orally.

[0060] For example, 17α-hydroxylase / C 17,20 -Lyase inhibitors can be administered transdermally. Alternatively, the additional therapeutic agent may be administered parenterally. 17,20 -rear The enzyme inhibitors can be administered orally, such as in tablets, caplets, or capsules, while In addition, the additional therapeutic agent may be administered intravenously. Such intravenously administered therapeutic agents include, but are not limited to, Not limited to, but includes docetaxel injections such as Taxotere®, Paclitaxel® Paclitaxel injections, such as sirolimus, and mitoxantrone injections, such as Novantrone® Additional therapeutic agents include leuprolide depot and other similar drugs such as Viadur (registered trademark). implants, such as Lupron Depot® and Lupron Depot®; triptorelin depots, e.g., Triptorelin star®; goserelin implants, depot or implants such as Zoladex®; It may be in the form of an injection.

[0061] 17α-hydroxylase / C 17,20 -The appropriate daily dose of lyase inhibitors should be determined The nature of the severity of the condition, the particular inhibitor, the route of administration, and the age, weight, and response of the individual patient. The answer depends on a variety of factors, including 17α-hydroxylase / C 17,20 -Lyase inhibitors A suitable daily dose is generally about 0.0001 mg / kg / day to about 1000 mg / kg / day in a single dose or multiple doses. / kg / day, or from about 0.001 mg / kg / day to about 200 mg / kg / day, or from about 0.01 mg / kg / day to about 200 mg / kg / day, Or it may be in the range of about 0.01 mg / kg / day to about 100 mg / kg / day.

[0062] In some embodiments, the 17α-hydroxylase / C 17,20 -Lyase inhibitors are approximately 0.004 mg / day to about 5,000 mg / day, or about 0.04 mg / day to about 3,000 mg / day, or about 0.4 mg / day to about 1500 mg / day In some embodiments, the 17α-hydroxylase / C 17,20 -rear The enzyme inhibitor is administered in a single or multiple doses at a dose of about 0.1 mg / day to about 2000 mg / day, or at a dose of about 1 mg / day to about 2000 mg / day. mg / day, or about 50 mg / day to about 2000 mg / day, or about 100 mg / day to about 1500 mg / day, or about 5 mg / day to about 1,000 mg / day, or about 5 mg / day to about 900 mg / day, or about 10 mg / day to about 800 mg / day, or about 15 mg / day It can be administered in an amount of about 700 mg / day, or about 20 mg / day to about 600 mg / day, or about 25 mg / day to about 500 mg / day. .

[0063] In some embodiments, 17α-hydroxylase / C 17,20 -lyase inhibitors are It is administered with additional anticancer drugs such as toxantrone, paclitaxel, or docetaxel. For example, a method for treating cancer in a mammal may include administering to a mammal an amount of abiraterone acetate and For example, abiraterone acetate is administered in an amount of about 0.01 mg / kg / The dose of mitoxantrone may be administered at a rate of about 0.1 mg / m 2 ~about 20m g / m 2 Preferably, mitoxantrone is administered once every 21 days over a period of about 10 to about 20 minutes. It is administered over a period of time.

[0064] Also, a method for treating cancer in a mammal includes combining an amount of abiraterone acetate and an amount of In one embodiment, abiraterone acetate is administered at a dose of about 0. 01 mg / kg / day to about 100 mg / kg / day, and paclitaxel can be administered at about 1 mg / m 2 ~about 175mg / m 2 Preferably, paclitaxel is administered once every three months at a dose of about 2 to 10 mg / kg. It is administered over a period of approximately 5 hours.

[0065] Additionally, a method for treating cancer in a mammal includes comprising administering to a mammal an amount of abiraterone acetate and an amount of For example, abiraterone acetate is administered at a dose of about 0.01 mg / kg / day to about 0.2 mg / kg / day of docetaxel. and docetaxel at about 1 mg / m 2 ~about 100mg / m 2 Preferably, docetaxel is administered once every three weeks over about 1 to about 2 hours. It is administered.

[0066] In some embodiments, 17α-hydroxylase / C 17,20 -Lyase inhibitors are Lumbar blockers (including but not limited to leuprolide, goserelin, or triptorelin) For example, one for treating cancer in a mammal may be administered with an anti-cancer drug, such as The treatment also involves administering an amount of abiraterone acetate and an amount of leuprolide. The amount of abiraterone acetate may be from about 0.01 mg / kg / day to about 100 mg / kg / day, and may be administered by lubrication. The amount of isopropyl alcohol may be from about 0.01 mg to about 200 mg for a period of from about 3 days to about 12 months. Generally, leuprolide is administered at a dose of approximately 3.6 mg for a period of approximately 3 days to approximately 12 months. It is given.

[0067] Additionally, a method for treating cancer in a mammal includes comprising administering to a mammal an amount of abiraterone acetate and an amount of For example, the amount of abiraterone acetate is about 0.01 mg / kg / day to about 100 mg / kg / day, and the amount of goserelin may be about 0.01 mg / kg / day for about 28 days to about 3 months. Preferably, goserelin is administered at a dose of about 3.6 mg to about 20 mg for a period of about 28 days to about 3 months. It is administered in an amount of 10.8 mg.

[0068] In some embodiments, the method for treating cancer in a mammal comprises administering an amount of acetylcholine to a mammal. For example, abiraterone acetate and an amount of triptorelin are administered. The amount of triptorelin may be about 0.01 mg / kg / day to about 100 mg / kg / day, and the amount of triptorelin may be about 1 month. Triptorelin may be administered at a dose of about 0.01 mg to about 20 mg for a period of about one month. It is administered in an amount of approximately 3.75 mg.

[0069] Also in one embodiment, the method for treating cancer in a mammal includes administering an amount of abiotic acetate. The method includes administering laterone and an amount of seocalcitol. For example, the method includes administering about 0. Abiraterone acetate in amounts of 0.01 mg / kg / day to about 100 mg / kg / day, and This includes administering a dose of seocalcitol (e.g., about 100 μg / day).

[0070] In another embodiment, the method for treating cancer in a mammal comprises administering an amount of abirate acetate to a mammal. For example, the method includes administering about 0.01 mg / kg / dose of bicalutamide. Abiraterone acetate in an amount of about 1 mg / kg / day to about 100 mg / kg / day, and bicarboxamide in an amount of about 1 mg / day to about 300 mg / day. This includes administering mido.

[0071] In yet another embodiment, the method for treating cancer in a mammal comprises administering an amount of acetylcholine to a mammal. The method includes administering biraterone and an amount of flutamide. For example, the method includes administering about 0.01 mg Abiraterone acetate in an amount of about 1 mg / kg / day to about 100 mg / kg / day, and fulvestib in an amount of about 1 mg / day to about 2000 mg / day. This includes administering tamido.

[0072] Additionally, a method for treating cancer in a mammal includes administering an amount of 17α-hydroxylase / C 17, 20 -lyase inhibitors (such as abiraterone acetate), and a certain amount of, but not limited to, luteinoids (including but not limited to hydrocortisone, prednisone, or dexamethasone) For example, the method may include administering from about 50 mg / day to about 2000 mg / day. Abiraterone acetate in an amount of about 0.01 mg / day to about 500 mg / day of hydrocortisone is administered. In another embodiment, the method includes administering to the patient an amount of about 500 mg / day to about 1500 mg / day. Administer abiraterone acetate and hydrocortisone in an amount of about 10 mg / day to about 250 mg / day. may include.

[0073] The method for treating cancer also includes administering to a subject an amount of 17α-hydroxylase / C 17,20 -Lyase inhibitors (such as abiraterone acetate) and a certain amount of glucocorticoids (such as prednisone). For example, the method may include administering vinegar in an amount of about 50 mg / day to about 2000 mg / day. and prednisone in an amount of about 0.01 mg / day to about 500 mg / day. The method also includes administering abiraterone acetate in an amount of about 500 mg / day to about 1500 mg / day. and administering prednisone in an amount of about 10 mg / day to about 250 mg / day.

[0074] Additionally, the method for treating cancer also includes administering to a subject an amount of 17α-hydroxylase / C 17,20 - Lyase inhibitors (such as abiraterone acetate) and certain amounts of glucocorticoids (dexamethasone, For example, the method may include administering from about 50 mg / day to about 2000 mg / day of a steroid hormone. Abiraterone acetate in an amount of about 0.01 mg / day to about 500 mg / day of dexamethasone The method may also include administering acetic acid in an amount of about 500 mg / day to about 1500 mg / day. and administering bilaterin in an amount of about 0.5 mg / day to about 25 mg / day of dexamethasone. This can be done.

[0075] (17α-hydroxylase / C 17,20 -a composition comprising a lyase inhibitor and an additional therapeutic agent In some embodiments, the composition comprises 17α-hydroxylase / C 17,20 -Lyase inhibitor The present invention also includes a combination of a medicament for treating rheumatoid arthritis, preferably abiraterone acetate, with any of the therapeutic agents listed above. 17α-hydroxylase / C 17,20 -Lyase inhibitor and additional therapeutic agent are administered in separate combinations Whether administered as a single composition or as a single composition, the compositions The compositions may take a variety of forms. For example, the compositions may be in the form of a solution, suspension, or the like, depending on the intended route of administration. It may take the form of a liquid, emulsion, tablet, pill, capsule, powder or sustained release formulation.

[0076] For topical or transdermal administration, the compositions may be in the form of a solution, gel, ointment, cream, suspension, or salve. It can be formulated as:

[0077] For oral administration, the composition may be in the form of a tablet, pill, or other suitable formulation for oral ingestion by the patient to be treated. as tablets, sugar-coated tablets, troches, capsules, liquids, gels, syrups, slurries, suspensions, etc. Can be formulated.

[0078] The compositions may also be used in suppositories containing conventional suppository bases such as cocoa butter or other glycerides. They can also be formulated in rectal or vaginal compositions, such as medicinal or retention enemas.

[0079] In addition to the formulations described previously, the compositions can also be formulated as a depot preparation. The therapeutic formulations can be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. For example, the therapeutic agent may be immersed in a suitable polymeric or hydrophobic material (e.g., in an acceptable oil). as emulsions) or with ion exchange resins, or as sparingly soluble derivatives, e.g. It can be formulated as a salt.

[0080] Additionally, the compositions may be incorporated into sustained release systems, such as semipermeable matrices of solid polymers containing the composition. Various forms of sustained-release materials have been established and are well known to those skilled in the art. Sustained-release capsules may last for hours, days, or weeks, depending on their chemical nature. The compositions can be released over a period of several months. For example, sustained release capsules can be administered for 100 days or more. Depending on the chemical nature and biological stability of the composition, the composition can be released safely. Further strategies for stabilization can be employed.

[0081] The composition may further comprise a pharma- ceutically acceptable carrier. The term "carrier" refers to Diluents, adjuvants (e.g., Freund's adjuvant (complete and The composition may include a carrier, excipient, or vehicle.

[0082] For parenteral administration, the compositions may be administered in the following carriers: sterile diluents (water for injection, saline, etc.) Water, non-volatile oil, polyethylene glycol, glycerin, propylene glycol or other synthetic solvents, etc.); antibacterial agents (such as benzyl alcohol or methylparaben); antioxidants agents (such as ascorbic acid or sodium bisulfite); chelating agents (such as ethylenediaminetetraacetic acid buffers (such as acetates, citrates, or phosphates); and tonicity adjusters (sodium chloride or Parenteral formulations may include one or more of the following: glass or in a plastic ampoule, disposable syringe, or multi-dose vial. Can be enclosed.

[0083] For oral solid formulations, suitable carriers include sugars, for example, lactose, sucrose, mannitol, and Bulking agents such as sorbitol; corn starch, wheat starch, rice starch, potato starch Potato starch, gelatin, tragacanth gum, methylcellulose, hydroxypropyl methylcellulose Cellulose such as cellulose, sodium carboxymethylcellulose, fats and oils a granulating agent; and a binder such as microcrystalline cellulose, gum tragacanth or gelatin. Cross-linked polyvinylpyrrolidone, agar, or alginic acid or its salts (sodium alginate disintegrants such as cornstarch, Primogel, or cornstarch; magnesium stearate; lubricants such as silica or sterotes; flow enhancers such as colloidal silicon dioxide sweetening agents such as sucrose or saccharin; or peppermint, methyl salicylate, or oleic acid. If desired, the solid dosage form may be flavored using standard techniques with sugars. The pharmaceutical composition may be coated or enteric coated.

[0084] For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, phosphate buffered saline (PBS), In all cases, the composition must be sterile and syringeable. It should be fluid to the extent that it is easy to inject. The composition should be stable under the conditions of manufacture and storage. and must be protected from the contaminating action of microorganisms such as bacteria and fungi. The carrier may be, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, etc.), and liquid polyethylene glycol, and The appropriate fluidity can be achieved, for example, by using a coating such as lecithin. In the case of dispersions, the required particle size is maintained, and surfactants are used to maintain the particle size. Prevention of the action of microorganisms can be achieved by the use of various antibacterial and antifungal agents, e.g., parabens, chlorella, chloroform ... This can be achieved using isobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, the composition may contain isotonic agents, for example, sugars; polysaccharides such as mannitol, sorbitol, etc. It is preferred to include sodium chloride. Prolonged absorption of the injectable composition is achieved by adding Include agents that delay absorption, such as aluminum monostearate and gelatin. This can be brought about by

[0085] For intravenous administration, the composition is preferably administered in Hank's solution, Ringer's solution, or It can be formulated as a solution in a physiologically compatible buffer, such as physiological saline buffer. The formulation may contain formulatory agents such as suspending, stabilizing and / or dispersing agents. In embodiments, the compositions are formulated as sterile solutions.

[0086] For transmucosal administration, penetrants appropriate to the barrier to be permeated can be used in the formulation. Penetrants are well known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be via the use of nasal sprays or suppositories. It can be achieved.

[0087] For administration by inhalation, the composition can be mixed with a suitable propellant, e.g., dichlorodifluoromethane , trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other Formulated as an aerosol spray from a pressurized container or nebulizer using a suitable gas. In the case of a pressurized aerosol, the dosage unit may be provided with a valve to deliver a metered amount. The composition of the inhaler or insufflator may be determined by the following: Capsules and cartridges of the invention can be formulated with the composition and a suitable powder base such as lactose or starch. The formulation can include a powder mixture with the agent.

[0088] Pharmaceutical compositions can be prepared by conventional mixing, dissolving, granulating, dragee-forming, triturating, emulsifying, encapsulating, entrapping, or other methods. or by a process of freeze-drying.

[0089] 17α-hydroxylase / C 17,20 -An example of a composition comprising a lyase inhibitor and an additional therapeutic agent an oral composition or oral administration comprising abiraterone acetate in combination with a steroid; For example, oral compositions are suitable for administration in solid dosage forms such as pills, tablets, or capsules. Oral compositions may contain about 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, g, 350mg, 400mg, 450mg, 500mg, 550mg, 600mg, 650mg, 700mg, 750mg, 800mg, 850mg, The oral compositions may contain 900 mg, 950 mg, or 1000 mg of abiraterone acetate. 25mg, 0.5mg, 0.75mg, 1.0mg, 1.25mg, 1.5mg, 1.75mg, 2.0mg, 2.25mg, 2.5mg, 2.75mg , 3.0mg, 3.25mg, 3.5mg, 3.75mg, 4.0mg, 4.25mg, 4.5mg, 4.75mg, 5.0mg, 7.5mg, 10mg , 20 mg, 30 mg, 40 mg, or 50 mg of a steroid such as a glucocorticoid. do.

[0090] In one embodiment, the oral composition comprises about 50 mg to about 500 mg of abiraterone acetate and about 0.2 Steroids such as hydrocortisone, prednisone, or dexamethasone in amounts of 5 mg to about 3.5 mg In another embodiment, the composition may comprise about 50 mg to about 300 mg of abiraterone acetate, and and about 1.0 mg to about 2.5 mg of hydrocortisone, prednisone, or dexamethasone. In another embodiment, the composition may comprise about 50 mg to about 300 mg of acetic acid. The composition may contain abiraterone acid and about 0.5 mg to about 3.0 mg of a steroid. For example, oral The composition contains 250 mg of abiraterone acetate; 1.25 mg or 2.0 mg of hydrocortisone, prednisone and one or more carriers, excipients, diluents or further The oral composition may be a tablet containing 250 mg of abiraterone acetate; 1.25 mg of abiraterone acetate; g or 2.0 mg of a steroid such as hydrocortisone, prednisone, or dexamethasone; and and one or more carriers, excipients, diluents or further ingredients.

[0091] The descriptions contained herein are for purposes of illustration and not for purposes of limitation. The methods and compositions described herein may incorporate any of the features described herein, either alone or in combination. may be included in combination with any other feature described herein. In addition, obvious changes, modifications, and variations may occur to those skilled in the art. Additionally, all references cited hereinabove will come to mind as being incorporated by reference in their entirety. No. 6,399,433, filed on Oct. 23, 2003, and which is hereby incorporated in its entirety for all relevant purposes.

Claims

1. A prostate cancer treatment comprising abiraterone acetate or a pharma- ceutical acceptable salt thereof, and prednisolone. A pharmaceutical composition for treating adenocarcinoma, comprising the abiraterone acetate or the pharma- ceutical acceptable salt thereof. and the prednisolone are administered in combination or separately in therapeutically effective amounts. The pharmaceutical composition.

2. The therapeutically effective amount of abiraterone acetate or a pharma- ceutical acceptable salt thereof is 500 mg / The pharmaceutical composition according to claim 1, wherein the dosage is from 1 to 1500 mg / day.

3. 3. The method of claim 2, wherein the therapeutically effective amount of prednisolone is 0.25 mg / day to 50 mg / day. A pharmaceutical composition comprising:

4. 3. The method of claim 2, wherein the therapeutically effective amount of prednisolone is 5 mg / day to 10 mg / day. Pharmaceutical compositions.

5. 5. The pharmaceutical composition of claim 4, wherein the therapeutically effective amount of prednisolone is 10 mg / day.

6. The prednisolone may be prednisolone acetate, prednisolone sodium phosphate, or The pharmaceutical composition according to claim 1, wherein the compound is selected from the group consisting of rednisolone tebutate.

7. refractory rheumatoid arthritis, comprising abiraterone acetate or a pharma- ceutical acceptable salt thereof, and prednisolone A pharmaceutical composition for treating prostate cancer, comprising: The acceptable salt and the prednisolone are administered in therapeutically effective amounts, either in combination or separately. The pharmaceutical composition is administered.

8. The therapeutically effective amount of abiraterone acetate or a pharma- ceutical acceptable salt thereof is 500 mg / The pharmaceutical composition according to claim 7, wherein the dosage is from 1 to 1500 mg / day.

9. 9. The method of claim 8, wherein the therapeutically effective amount of prednisolone is 0.25 mg / day to 50 mg / day. A pharmaceutical composition comprising:

10. 9. The method of claim 8, wherein the therapeutically effective amount of prednisolone is 5 mg / day to 10 mg / day. Pharmaceutical compositions.

11. 11. The pharmaceutical composition of claim 10, wherein the therapeutically effective amount of prednisolone is 10 mg / day. 。

12. The prednisolone may be prednisolone acetate, prednisolone sodium phosphate, or The pharmaceutical composition according to claim 7, wherein the compound is selected from rednisolone tebutate.